PRINCETON, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will be presenting at the following three investor conferences during November 2007:
-- Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference being
held from November 5-7, 2007 at the New York Palace Hotel in New York
City. Schaefer Price, Pharmasset's President & Chief Executive
Officer, will provide an overview of the company on Tuesday,
November 6, 2007 at 2:20 PM (ET).
-- CIBC World Markets 18th Annual Healthcare Conference being held from
November 5-7, 2007 at the Waldorf-Astoria Hotel in New York City.
Schaefer Price, Pharmasset's President & Chief Executive Officer, will
provide an overview of the company on Wednesday, November 7, 2007 at
8:00 AM (ET).
-- JMP Securities Sector Focus Conference being held on November 13, 2007
at the Four Seasons Hotel in Boston. Dr. Michael Otto, Pharmasset's
Executive Vice President, Pharmaceutical Research, will provide an
overview of the company and participate in a company-related
conversation on Tuesday, November 13, 2007 at 3:00 PM (ET).
To access a simultaneous webcast of each presentation via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of each presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.
The archived replay of the webcast will be available on Pharmasset's website for a limited period of time following each conference. The investor presentation will be available for download in PDF format following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is enrolling a 28-day Phase 1 clinical trial in combination with Pegasys(R) and Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Alan Roemer, Vice President
Investor Relations & Corporate Communications
Office: (609) 613-4125
|SOURCE Pharmasset, Inc.|
Copyright©2007 PR Newswire.
All rights reserved